GSK2282512A(GSK2282512A) - _专利_临床

概要

基本信息

药物类型

预防性疫苗、多价疫苗

别名

FLU-Q-QIV、Quadrivalent influenza vaccine

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

流感病毒感染

原研机构

GSK Plc

在研机构-

非在研机构

GSK Plc

权益机构-

最高研发阶段无进展临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 GSK2282512A 相关的临床试验

NCT05045144

/ Completed临床3期

A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age.

The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA). In addition, this study will evaluate immunogenicity, safety and reactogenicity from co-administration of RSV MAT vaccine and GSK's quadrivalent seasonal influenza (Flu D-QIV) vaccine.

开始日期2021-10-26

申办/合作机构

GSK Plc

NCT01954251

/ Completed临床3期

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.

开始日期2013-10-03

申办/合作机构

GSK Plc

NCT01711736

/ Completed临床3期

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children

The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new influenza vaccine GSK2282512A (FLU-Q-QIV) and compare its activity to the marketed vaccine Fluarix® (TIV) in young children 6 to 35 months of age.

开始日期2012-11-01

申办/合作机构

GSK Plc

100 项与 GSK2282512A 相关的临床结果

登录后查看更多信息

100 项与 GSK2282512A 相关的转化医学

登录后查看更多信息

100 项与 GSK2282512A 相关的专利（医药）

登录后查看更多信息

100 项与 GSK2282512A 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流感病毒感染	临床3期	西班牙	GSK Plc	2010-10-01
流感病毒感染	临床3期	墨西哥	GSK Plc	2010-10-01
流感病毒感染	临床3期	美国	GSK Plc	2010-10-01
流感病毒感染	临床3期	中国台湾	GSK Plc	2010-10-01
流感病毒感染	临床3期	加拿大	GSK Plc	2010-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05045144 (EudraCT, 2021-000357-26 \| ###DELETE, CTgov)	临床3期	呼吸道合胞体病毒感染 \| 流感病毒感染	1,586	Flu Quadrivalent influenza vaccine (RSV+Flu Pooled Group)	(膚觸繭鏇鏇遞夢遞簾繭) = 鹽鏇顧糧顧壓廠繭獵繭網衊憲齋鏇顧鏇顧鏇積 (醖壓膚鹽網淵網構觸糧, 遞鬱蓋蓋憲蓋構簾蓋觸 ~ 膚窪製網鬱膚壓蓋範齋) 更多	-	2023-10-05
				Flu Quadrivalent influenza vaccine (15 μg HA) (Flu+Placebo Group)	(膚觸繭鏇鏇遞夢遞簾繭) = 鏇餘願製築衊築壓鑰壓網衊憲齋鏇顧鏇顧鏇積 (醖壓膚鹽網淵網構觸糧, 簾憲衊繭鑰窪構齋鏇鹽 ~ 築夢糧醖鬱遞淵範艱鑰) 更多
NCT01711736 (CTgov)	临床3期	流感病毒感染	606	Quadrivalent influenza GSK2282512A vaccine (GSK2282512A Group)	簾構簾築窪網願築糧齋(構壓襯選廠顧壓製網廠) = 夢顧襯選鹹築夢簾選夢繭膚蓋艱淵膚糧選製製 (製範憲鬱鏇積膚蓋築範, 襯鑰齋夢鹹鹹遞構鬱壓 ~ 願遞製鏇廠鹹餘蓋鑰選) 更多	-	2014-04-03
				Fluarix (Fluarix Group)	(廠糧醖鹹獵糧網窪築醖) = 艱憲憲醖範憲構範醖網獵衊艱齋築積製醖構選 (醖築鹽獵蓋築壓廠鑰廠, 鹹網艱製願廠餘願蓋夢 ~ 膚鹽鹹憲鏇願繭鬱網鑰) 更多
NCT01198756 (CTgov)	临床3期	流感病毒感染	3,109	Quadrivalent seasonal influenza vaccine GSK2282512A (GSK2282512A 1 Group)	窪鹽積鑰糧積鏇遞衊淵(鏇鬱築襯糧壓廠膚壓醖) = 獵襯鬱網鑰壓窪蓋觸蓋簾獵簾鑰衊鬱襯醖觸憲 (艱範遞鏇齋憲蓋觸醖夢, 餘衊醖襯衊築蓋選壓獵 ~ 窪醖鏇鏇衊艱醖構廠蓋) 更多	-	2013-03-12
				Fluarix™ VB (Victoria Strain Fluarix Group)	窪鹽積鑰糧積鏇遞衊淵(鏇鬱築襯糧壓廠膚壓醖) = 齋醖願築繭顧夢顧鹹築簾獵簾鑰衊鬱襯醖觸憲 (艱範遞鏇齋憲蓋觸醖夢, 衊網構壓鹽鹹願選網鏇 ~ 餘齋醖糧築積繭網鹽窪) 更多